OneAscent Financial Services LLC Has $371,000 Stake in Pfizer Inc. $PFE

OneAscent Financial Services LLC reduced its position in shares of Pfizer Inc. (NYSE:PFE) by 61.4% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 14,541 shares of the biopharmaceutical company’s stock after selling 23,165 shares during the period. OneAscent Financial Services LLC’s holdings in Pfizer were worth $371,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in PFE. Vanguard Group Inc. grew its stake in shares of Pfizer by 1.9% in the second quarter. Vanguard Group Inc. now owns 533,363,457 shares of the biopharmaceutical company’s stock valued at $12,928,730,000 after acquiring an additional 10,198,330 shares in the last quarter. Geode Capital Management LLC boosted its holdings in Pfizer by 1.4% in the 2nd quarter. Geode Capital Management LLC now owns 127,471,481 shares of the biopharmaceutical company’s stock valued at $3,080,552,000 after purchasing an additional 1,820,634 shares during the period. Norges Bank acquired a new position in shares of Pfizer during the 2nd quarter worth approximately $2,270,157,000. Charles Schwab Investment Management Inc. increased its holdings in shares of Pfizer by 2.4% during the second quarter. Charles Schwab Investment Management Inc. now owns 49,165,032 shares of the biopharmaceutical company’s stock worth $1,191,760,000 after purchasing an additional 1,135,457 shares during the period. Finally, Fisher Asset Management LLC raised its position in shares of Pfizer by 2.0% in the second quarter. Fisher Asset Management LLC now owns 48,390,268 shares of the biopharmaceutical company’s stock valued at $1,172,980,000 after buying an additional 950,239 shares in the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Cantor Fitzgerald raised its price target on PFE to $27 from $24, providing an immediate buy-side catalyst that helped lift the stock. Why Is Pfizer Stock Rising Tuesday?
• Neutral Sentiment: Market commentary and analyst notes reiterate interest in PFE after the move; some analysts continue to debate valuation and targets, producing mixed near-term signals. Analysts Offer Insights on Healthcare Companies
• Neutral Sentiment: Opinion pieces and bulls (e.g., Seeking Alpha) argue long-term upside tied to portfolio diversification and pipeline execution, but these are forward-looking views rather than near-term drivers. Pfizer: The Great Healthcare Plan…
• Negative Sentiment: The U.S. Centers for Medicare & Medicaid Services added several Pfizer drugs to the next round of Medicare Drug Price Negotiations (including first Part B reimbursements), which could pressure pricing and revenues if negotiations force lower prices. US Medicare names Eli Lilly, Pfizer and AbbVie drugs…
• Negative Sentiment: Earnings previews warn Q4 results may decline versus prior periods, highlighting the risk of an earnings miss or softer guidance that could weigh on the stock. Earnings Preview: Pfizer (PFE) Q4 Earnings Expected to Decline
• Negative Sentiment: Competitive risk: Aclaris reported a hair-loss candidate that showed faster results than Pfizer’s Litfulo in preclinical tests, an early sign of therapeutic competition in a growth area. Aclaris Hair Loss Drug Shows Faster Results…
• Negative Sentiment: Wider structural concerns persist: commentary notes underperformance versus peers due to softer COVID-era product demand and an upcoming patent cliff, which are longer-term headwinds for growth. Pfizer vs. Merck Stock And JNJ
• Negative Sentiment: Balance-sheet note: analysis highlighting heavier debt usage may concern income-focused or risk-sensitive investors monitoring leverage and cash-flow resilience. These 4 Measures Indicate That Pfizer Is Using Debt Extensively

Pfizer Trading Up 2.4%

Shares of Pfizer stock opened at $26.49 on Wednesday. The firm’s 50 day moving average is $25.43 and its 200 day moving average is $25.01. The firm has a market capitalization of $150.61 billion, a PE ratio of 15.40 and a beta of 0.47. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $27.69. The company has a current ratio of 1.28, a quick ratio of 0.97 and a debt-to-equity ratio of 0.62.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share for the quarter, beating analysts’ consensus estimates of $0.79 by $0.08. The firm had revenue of $16.65 billion for the quarter, compared to analyst estimates of $16.94 billion. Pfizer had a net margin of 15.65% and a return on equity of 20.17%. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. Equities research analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, January 23rd will be given a $0.43 dividend. The ex-dividend date is Friday, January 23rd. This represents a $1.72 annualized dividend and a yield of 6.5%. Pfizer’s dividend payout ratio (DPR) is currently 100.00%.

Analyst Ratings Changes

PFE has been the topic of a number of recent research reports. UBS Group assumed coverage on Pfizer in a research note on Tuesday, January 6th. They set a “neutral” rating and a $25.00 price objective on the stock. Weiss Ratings reissued a “hold (c-)” rating on shares of Pfizer in a report on Thursday, January 22nd. BMO Capital Markets reaffirmed an “outperform” rating on shares of Pfizer in a research note on Wednesday, December 10th. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $26.00 price objective on shares of Pfizer in a research report on Wednesday, November 5th. Finally, Cantor Fitzgerald raised their target price on shares of Pfizer from $24.00 to $27.00 and gave the company a “neutral” rating in a report on Tuesday. Two equities research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Pfizer currently has an average rating of “Hold” and a consensus target price of $28.06.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.